Abstracts

DISCONTINUATIONS & VIROLOGIC RESPONSE IN LATE PRESENTERS WITH InSTI- OR PI-BASED ART

Active opportunistic infections and/or low CD4+T-cell (CD4+) counts are exclusion criteria in most clinical trials. Late presenters (LP) are therefore inadequately represented in studies comparing efficacy of antiretroviral regimens, leading to a lack of data on optimal treatment options. Our study aimed to investigate the efficacy and safety of first line ART with integrase-inhibitor (INSTI)…

AUTOLOGOUS NEUTRALIZING ANTIBODIES DRIVE VIRUS EVOLUTION DURING REBOUND AFTER ATI

Characterization of the viral dynamics and host immune pressures present during HIV-1 rebound after analytical treatment interruption (ATI) provides insight into the environment in which therapeutic and curative strategies must act. We studied plasma samples from a previously conducted clinical trial (NCT00051818) in which chronically-ART initiated participants underwent a single or multiple sequential ATIs. Single…

RAPID DEVELOPMENT OF AN INFANT-DERIVED HIV-1 BROADLY NEUTRALIZING ANTIBODY

HIV-infected infants develop broadly neutralizing plasma responses with more rapid kinetics and lower somatic hypermutation than adults, suggesting the ontogeny of infant responses could inform a better path to achievable vaccine targets. We previously isolated BF520.1, the first and only infant-derived broadly HIV-neutralizing antibody (bnAb). A thorough investigation of how BF520.1 developed will highlight possible…

PROFILING ANTIBODY CROSS-REACTIVITY AMONG SIV ISOLATES USING A PEPTIDE MICROARRAY

In the past decade, a number of broadly neutralizing human immunodeficiency virus (HIV) antibodies have been identified; however, tools for assessing antibody cross-reactivity are still relatively low throughput. Ultradense linear peptide arrays enable the determination of antibody reactivity to as many as six million peptides in a single assay. Identification of antibodies capable of binding…

RELATION OF CIN2 PROGRESSION WITH SERIAL CERVICOVAGINAL CYTOKINE/CHEMOKINE LEVELS

Women living with HIV are high-risk for cervical intraepithelial neoplasia-2 (CIN2), a potentially pre-cancerous diagnosis. We characterized longitudinal variations in cervicovaginal lavage (CVL) chemokine/cytokine levels and their temporal relation with CIN2 and its progression. N=104 HIV-positive women (age < 46) were selected from the Women’s Interagency HIV Study (WIHS). To avoid misclassification, we excluded women…

HPV GENOTYPING IN 1,088 ANAL HSIL CASES: EXPECTED AND UNEXPECTED RESULTS

High-grade squamous intraepithelial lesions (HSIL), the anal cancer precursors, are caused by high-risk human papillomavirus (hrHPV). HrHPV-negative HSILs occur occasionally in clinical practice and constitute an unexpected departure from that rule leading to diagnostic and therapeutic challenges. Using 1,088 simultaneously collected anal swab and histologic HSIL specimens, we aimed to determine the distribution of hrHPV…

PRIMARY HPV SCREENING IN WOMEN LIVING WITH HIV

Primary HPV Screening (PHS) utilizes an oncogenic human papillomavirus (oncHPV) assay as the initial cervical cancer screening test (instead of a Pap test). Recent US guidelines support PHS in women in the general population (30-65 years of age), and suggest oncHPV- women should be retested in 5 years. For oncHPV+ women, reflex HPV genotyping is…